Adelyn Schmidt
Associate Editor
Loyola University of Chicago J.D. 2027
The popularity of glucagon-like peptide-1 receptor agonists (GLP-1 drugs) such as Ozempic and Wegovy has transformed the market for weight-loss medications in the United States. Originally developed to treat type 2 diabetes, these drugs are now widely prescribed for weight management. However, demand has created nationwide shortages, prompting compounding pharmacies to produce customized versions of GLP-1 medications intended to replicate FDA-approved medications. In practice, however, this has enabled the rapid expansion of compounded GLP-1 drugs that mimic highly popular brand-name medications. Evidence of contamination, dosing errors, and serious adverse events linked to these products suggests that the current regulatory framework does not sufficiently protect consumers. Given these risks, Section 503A should be strengthened to prohibit pharmacies from producing copies of commercially available GLP-1 drugs altogether, even during shortages.
The growth of compounded GLP-1 drugs
GLP-1 drugs, including semaglutide and tirzepatide, have become some of the most sought-after medications in the United States. These drugs work by mimicking a hormone that regulates appetite and blood sugar levels, helping patients control diabetes and achieve significant weight loss. The surge in demand has created supply shortages, making it difficult for many patients to obtain FDA-approved medications. In response, compounding pharmacies began producing compounded GLP-1 drugs designed to mimic the active ingredients in brand-name products. Because compounded drugs may use FDA-approved ingredients but are not themselves FDA-approved, they bypass the rigorous safety and efficacy review required for commercial medications. These compounded formulations are frequently marketed as cheaper and more accessible alternatives to FDA-approved medications. However, their rapid proliferation has raised serious safety and regulatory concerns.
The legal framework for compounded drugs
Under current federal law, pharmacies may compound certain drugs when an FDA-approved medication is unavailable due to a shortage. The FDA regulates compounded drugs under Sections 503A and 503B of the FD&C Act. Section 503A governs traditional pharmacy compounding and allows pharmacists to prepare customized medications for individual patients based on a valid prescription. However, the statute prohibits compounders from producing drugs that are “essentially copies” of commercially available medications, except in limited circumstances (s.a, drug shortages). Compounded versions are often designed to resemble patented drugs without formally duplicating them.
The statute also provides that compounding must not occur “regularly or in inordinate amounts,” a standard intended to prevent pharmacies from functioning as de facto drug manufacturers. In practice, however, this language has proven difficult to enforce. Compounding pharmacies have continued producing GLP-1 formulations that closely resemble FDA-approved drugs while relying on the statute’s ambiguity to justify large-scale production.
Safety risks associated with compounded GLP-1 drugs
The widespread availability of compounded GLP-1 medications raises significant safety concerns. Unlike FDA-approved medications, compounded drugs are not subject to premarket review for safety, quality, or manufacturing consistency. Reports of adverse events linked to compounded GLP-1 medications have increased as these products have entered the market. Patients have experienced overdoses, hospitalizations, and severe side effects due to incorrect dosing or inconsistent drug concentrations.
Compounded medications also lack the standardized delivery systems used in FDA-approved GLP-1 drugs. While commercial products are typically distributed in prefilled injection pens with fixed dosages, compounded versions may be supplied in multi-dose vials with varying concentrations. This lack of standardization increases the risk of dosing errors and medication misuse. Additionally, some compounded products have been linked to contamination or adulteration, raising concerns about manufacturing quality and ingredient sourcing. These risks demonstrate the dangers of allowing compounded drugs that closely replicate complex biologic medications.
Section 503A should be strengthened
Although Section 503A was designed to preserve patient access during shortages, the statute’s exception for copying commercially available drugs has created a significant regulatory loophole. The allowance for compounding drugs that resemble FDA-approved medications, even in limited quantities, has enabled a parallel market for unapproved pharmaceutical products. Given the complexity of GLP-1 drugs and the growing evidence of safety risks associated with compounded versions, allowing pharmacies to compound copies of these medications in any amount undermines the FDA’s drug approval system. The risks of contamination, dosing errors, and inconsistent potency are particularly concerning for medications that affect metabolic and endocrine systems.
A more effective regulatory approach would eliminate the exception that permits compounding copies of commercially available drugs. Pharmacies should be permitted to compound medications only when a patient requires a customized formulation that cannot be obtained through FDA-approved products. Allowing compounders to replicate popular drugs, especially those already available through commercial manufacturers, creates unnecessary risks for patients.